These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 17378926)

  • 1. A retrospective nationwide case study on the use of a new antifungal agent: patients treated with caspofungin during 2001-2004 in Finland.
    Anttila VJ; Salonen J; Ylipalosaari P; Koivula I; Riikonen P; Nikoskelainen J
    Clin Microbiol Infect; 2007 Jun; 13(6):606-12. PubMed ID: 17378926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
    DiNubile MJ; Hille D; Sable CA; Kartsonis NA
    J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients.
    Betts R; Glasmacher A; Maertens J; Maschmeyer G; Vazquez JA; Teppler H; Taylor A; Lupinacci R; Sable C; Kartsonis N
    Cancer; 2006 Jan; 106(2):466-73. PubMed ID: 16353208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
    Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
    Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of caspofungin and amphotericin B for invasive candidiasis.
    Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
    N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients.
    Cesaro S; Giacchino M; Locatelli F; Spiller M; Buldini B; Castellini C; Caselli D; Giraldi E; Tucci F; Tridello G; Rossi MR; Castagnola E
    BMC Infect Dis; 2007 Apr; 7():28. PubMed ID: 17442100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies.
    Candoni A; Mestroni R; Damiani D; Tiribelli M; Michelutti A; Silvestri F; Castelli M; Viale P; Fanin R
    Eur J Haematol; 2005 Sep; 75(3):227-33. PubMed ID: 16104879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
    Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
    J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis.
    Maertens J; Glasmacher A; Herbrecht R; Thiebaut A; Cordonnier C; Segal BH; Killar J; Taylor A; Kartsonis N; Patterson TF; Aoun M; Caillot D; Sable C;
    Cancer; 2006 Dec; 107(12):2888-97. PubMed ID: 17103444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study.
    Kartsonis NA; Saah A; Lipka CJ; Taylor A; Sable CA
    J Antimicrob Chemother; 2004 May; 53(5):878-81. PubMed ID: 15044431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
    Aliff TB; Maslak PG; Jurcic JG; Heaney ML; Cathcart KN; Sepkowitz KA; Weiss MA
    Cancer; 2003 Feb; 97(4):1025-32. PubMed ID: 12569602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis.
    Betts RF; Nucci M; Talwar D; Gareca M; Queiroz-Telles F; Bedimo RJ; Herbrecht R; Ruiz-Palacios G; Young JA; Baddley JW; Strohmaier KM; Tucker KA; Taylor AF; Kartsonis NA;
    Clin Infect Dis; 2009 Jun; 48(12):1676-84. PubMed ID: 19419331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia.
    Lafaurie M; Lapalu J; Raffoux E; Breton B; Lacroix C; Socié G; Porcher R; Ribaud P; Touratier S; Molina JM
    Clin Microbiol Infect; 2010 Aug; 16(8):1191-6. PubMed ID: 19735276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Caspofungin for the treatment of candidaemia in patients with haematological malignancies.
    Pagano L; Fianchi L; Fanci R; Candoni A; Caira M; Posteraro B; Morselli M; Valentini CG; Farina G; Mitra ME; Offidani M; Sanguinetti M; Tosti ME; Nosari A; Leone G; Viale P
    Clin Microbiol Infect; 2010 Mar; 16(3):298-301. PubMed ID: 19549221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study.
    Kartsonis NA; Saah AJ; Joy Lipka C; Taylor AF; Sable CA
    J Infect; 2005 Apr; 50(3):196-205. PubMed ID: 15780413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasive candidiasis treated in the intensive care unit: observations from a randomized clinical trial.
    DiNubile MJ; Lupinacci RJ; Strohmaier KM; Sable CA; Kartsonis NA
    J Crit Care; 2007 Sep; 22(3):237-44. PubMed ID: 17869975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
    Maertens J; Raad I; Petrikkos G; Boogaerts M; Selleslag D; Petersen FB; Sable CA; Kartsonis NA; Ngai A; Taylor A; Patterson TF; Denning DW; Walsh TJ;
    Clin Infect Dis; 2004 Dec; 39(11):1563-71. PubMed ID: 15578352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of caspofungin in obese patients.
    Ryan DM; Lupinacci RJ; Kartsonis NA
    Med Mycol; 2011 Oct; 49(7):748-54. PubMed ID: 21466264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of caspofungin in HIV-infected individuals.
    Waters L; Nelson M
    Expert Opin Investig Drugs; 2007 Jun; 16(6):899-908. PubMed ID: 17501701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study.
    Winkler M; Pratschke J; Schulz U; Zheng S; Zhang M; Li W; Lu M; Sgarabotto D; Sganga G; Kaskel P; Chandwani S; Ma L; Petrovic J; Shivaprakash M
    Transpl Infect Dis; 2010 Jun; 12(3):230-7. PubMed ID: 20070619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.